Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (29981)	1/8/2000 10:41:00 PM
From: Torben Noerup Nielsen	Respond to of 32384

Celery, Mathematics - including Statistics - was my first Great Love (that was before I discovered girls and found out what the hard problems in Life really were...) and as far as I can tell, this wasn't really a statistical study at all. But that doesn't render it invalid. All you need to interpret the results is Occam's Razor. The only portion of the study that might submit to statistics was the part that dealt with the side effects and I believe that part was fine. The side effects appear relatively trivial compared to the disease and they disappeared upon cessation of the medication. Does someone here have enough medical knowledge to give me a good reason why Targretin should not be the first line treatment of choice for CTCL? It seems to be more benign than the alternatives and if it works, the alternatives may not be necessary. Somewhere in there was a comment to the effect that prior exposure to Interferon Alpha tended to worsen the side effects. If that is the case, why not go directly to Targretin first? Apparently you can use Targretin repeatedly and if it doesn't work well the first time, you always have the option of trying the other therapies. Yes, I have a financial interest in this. But I don't think it's enough to make me want to use this drug on patients just to make a few more dollars for Ligand. It simply seems to be common sense. Unfortunately, I'm just a lay person with very limited understanding of the underlying issues and I may be naive in my approach. Regards, Torben